Semester VII · PCI syllabus 2026
Pharmacovigilance
BP705T
3 credits
Theory
Coming soon
Unit 1: Fundamentals of Pharmacovigilance
- a) Concept, history, and importance of pharmacovigilance b) Basic drug classification systems (introductory overview only): c) ATC classification, ICD
- ATC system
- ICD d) Drug-related problems and medication safety e) Drug safety considerations in special populations:
- Paediatrics
- Geriatrics
- Pregnancy and lactation
Unit 2: Pharmacovigilance Systems and Regulatory Framework
- a) Objectives and functions of pharmacovigilance b) Methods of pharmacovigilance data collection:
- Spontaneous reporting
- Cohort and case-control studies c) Global pharmacovigilance systems:
- WHO International Drug Monitoring Programme
- Role of CIOMS and major regulatory agencies (e.g., USFDA, EMA) d) Pharmacovigilance Programme of India (PvPI) e) Establishment and role of ADR Monitoring Centres
Unit 3: Adverse Drug Reactions (ADRs)
- a) Classification and types of ADRs b) Mechanisms and risk factors for ADRs c) Methods of ADR monitoring, detection, and reporting d) Assessment of causality, severity, predictability, and preventability of ADRs e) Management of ADRs f) Online reporting mechanisms and databases (WHO-ART, VigiBase, Vigiflow, Oracle Argus, OpenVigil software). g) MEDRA
Unit 4: Immunovigilance and Other Disciplines of Pharmacovigilance
- a) Definition, scope, and significance of immunovigilance, cosmetovigilance, nutraceutical-vigilance, materiovigilance, herbovigilance, ecopharmacovigilance, and hemovigilance b) Vaccination failure and vaccine pharmacovigilance (vaccinovigilance) c) Overview of adverse events following immunization (AEFIs) d) Immunization safety monitoring systems in India
Unit 5: Risk Communication, Evaluation, Management, and ICH
- Guidelines and immunovigilance b) Communication in drug safety crisis management c) Communication with regulatory agencies, business partners, and healthcare facilities d) Analysis of real-world case studies and lessons learnt e) Emerging trends and challenges in pharmacovigilance and immunovigilance f) Overview of safety data generation g) Objectives of ICH guidelines h) Expedited and aggregate reporting i) Individual Case Safety Reports (ICSRs) j) Periodic Safety Update Reports (PSURs) k) Post-approval expedited reporting l) Good Clinical Practices (GCPs) regulation 2019 m) Application of pharmacogenomics and pharmacometrics in pharmacovigilance
Is subject ka content (video/notes) abhi production mein hai — syllabus official PCI curriculum se hai, jaise-jaise units record honge yahan live ho jaayenge.